An entire session at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda was devoted to the PURPOSE 1 and PURPOSE 2 studies of the six-monthly injectable PrEP drug lenacapavir, which reflects its importance as a step forward in HIV prevention.
Lenacapavir for PrEP has recently received positive decisions by drug regulators in the US and Europe. Its brand name will be slightly different in those two markets – Yeztugo and Yeytuo, respectively (and when used as part of HIV treatment, it’s Sunlenca). During the conference, the World Health Organization issued guidelines recommending it. The dose is two 1.5ml vials of lenacapavir, given as subcutaneous injections, every six months (plus an oral ‘loading dose’ when starting – more on this below).
Two presentations in the PURPOSE session covered young people, the oral ‘loading dose’, interactions with other drugs and situations such as being late for an injection. Another covered pregnancy and breastfeeding, and has already been reported by aidsmap.
Read the full news story at aidsmap.
All aidsmap reports from IAS 2025 can be accessed here.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.